Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer
PSTV•Coverage agreement for CNSide assay
July 21 (Reuters) - Plus Therapeutics Inc PSTV.O:
- Plus Therapeutics secures regional coverage agreement with Medical Mutual for CNSide® cerebrospinal fluid assay for metastatic CNS cancer
- Plus Therapeutics - to change name to Cerenome, and ticker to CNSY on August 3, 2026



